Treatment-Resistant Depression: What It Means and What Options Exist

Last reviewed: 07/11/2026

Reviewed by: Dr. Kiesa Kelly

If you have tried an antidepressant — maybe two — and still feel the weight of depression, you are not doing anything wrong, and you are not out of options. Treatment-resistant depression is a clinical term for depression that has not responded to standard first-line treatment. The name sounds final. In practice, it rarely is. Up to about a third of people with major depression do not reach full remission after their first medications, which makes this experience common, well studied, and workable [1].

The hard part is the in-between place it puts you in. You have done what you were told, the relief has not come, and it is easy to conclude that the problem is you, or that nothing will help. This article is meant to replace that conclusion with a clearer map: what "treatment-resistant" actually means, why depression sometimes resists the first thing tried, and the real range of options — including options that have nothing to do with adding another pill.

In this article, you'll learn:

• What treatment-resistant depression means clinically, and how the definition varies

• How common it is, and how it differs from a partial response

• Why depression can resist first-line treatment — including factors that often get missed

• What options exist, from therapy and reassessment to prescriber-directed treatments

• Where a psychologist's assessment and therapy fit, and honest limits on our role

• Concrete questions to bring to your next appointment

What treatment-resistant depression actually means

At its simplest, treatment-resistant depression describes major depression that has not gone into remission despite an adequate course of standard antidepressant treatment. The most widely used threshold is two or more adequate antidepressant trials in the same episode without reaching remission [1]. If your symptoms have improved but not enough, that is usually called a partial response — technically, less than about a 50% drop in depression-rating scores — which is a related but distinct situation [1]. If depression is not improving despite treatment, one of the most useful early steps is a careful look at the fuller clinical picture, which is part of what a thorough psychological assessment is designed to do.

The word "adequate" is doing a lot of quiet work in that definition. A medication trial only counts as adequate if it was taken at a therapeutic dose, for long enough (often six to eight weeks), and taken consistently [1]. A great deal of what looks like resistance is actually an under-treated trial — a dose that was never raised, a medication stopped early because of side effects, or a stretch of missed doses during a hard month. Before the treatment-resistant label is applied, a clinician should rule those out first [1].

It is also worth knowing that experts do not fully agree on a single definition. A 2023 review in World Psychiatry found many competing definitions, which is one reason prevalence estimates range so widely — roughly 30% in research settings, but anywhere from about 6% to 55% in real-world practice depending on the criteria used [2]. Some definitions require the two failed medications to come from different classes; others simply count two adequate trials [2]. The label is a useful signpost, not a fixed biological category.

Three ideas worth correcting early

"Treatment-resistant means untreatable." It does not. It means the standard first-line options have not produced remission yet — not that no treatment can help. The evidence base for what to try next is substantial, and outcomes improve for many people who move past the first steps [1][2].

"If two medications didn't work, nothing will." Antidepressants are one tool, not the whole toolbox. Response rates do tend to fall with each successive medication tried, which is exactly why the next move is often not a third medication of the same kind, but a change in strategy — therapy, augmentation, reassessment, or a different modality [3].

"Resistance means you didn't try hard enough." Resistance is about the fit between a treatment and a particular person's biology and life, not about willpower or moral failure. Framing it as personal failure is both inaccurate and, clinically, part of what keeps people stuck.

How common it is, and why "resistant" isn't the whole story

Large studies help put the numbers in perspective. In the landmark STAR*D trial — the biggest real-world study of sequential depression treatment — roughly a third of participants reached remission on their first medication, and the share reaching remission fell with each additional step [3][4]. In other words, needing more than one attempt is the norm for a large minority of people, not a rare outlier.

The most useful reframe here is measurement. When treatment is guided by a validated symptom scale rather than a general impression, it is far easier to tell the difference between "no response," "partial response," and "remission" — and to catch a stalled plan early. Tracking mood over time with a short, standardized tool such as the PHQ-9 turns a vague "I still feel bad" into data your care team can act on. This is the core idea behind measurement-based care, and it is one of the quieter reasons some treatment plans stall: without measurement, a partial response can be mistaken for a failure, or a slow-but-real improvement can be abandoned too soon.

🧭 Key takeaway: Treatment-resistant depression is common and defined by not-yet-reaching-remission after adequate trials — it is a description of where treatment stands, not a verdict on whether you can get better.

Why depression can resist first-line treatment

When depression does not lift, the most productive question is usually not "which medication next?" but "what are we actually treating?" Several recurring factors explain a large share of apparent resistance, and most of them are addressable.

The trial may not have been adequate. As above, an under-dosed or short trial is the single most common explanation. This is fixable, and it is the first thing a good prescriber revisits [1].

The diagnosis may be incomplete. Depression rarely arrives alone. What is being treated as unipolar depression is sometimes part of a bipolar-spectrum pattern, which responds to a different class of treatment entirely — treating it as ordinary depression can stall progress or make things worse. Consider a concrete picture. You have been on two antidepressants over a year. Each one lifted your mood briefly and unusually high — a week or two of little sleep, racing plans, and unusual confidence — before the floor dropped out again. Your prescriber treated the crashes as the "real" problem and kept adjusting the antidepressant. What never got asked about were the brief highs, which are exactly the piece a fuller evaluation would want to understand.

Or: you have carried "depression" since your twenties, but the steadier truth is that you have never been able to start boring tasks, you lose track of time, and your self-worth has eroded under years of unfinished work and missed deadlines. Antidepressants take the sharpest edge off the despair but do nothing for the underlying executive-function struggle — because part of what is happening may be unrecognized ADHD, not depression alone. Naming that changes the whole plan.

Trauma may be underneath. Depression that will not shift sometimes sits on top of unprocessed trauma. When intrusive memories, hypervigilance, or emotional numbing are part of the picture, a depression-only plan can keep missing the target; screening for post-traumatic symptoms with a tool like the PCL-5 can help decide whether trauma-focused care belongs in the plan.

Co-occurring anxiety can blunt response. Significant anxiety alongside depression is common and is associated with a harder treatment course. Sorting out how much anxiety is in the mix — a brief measure such as the GAD-7 is a starting point — can reshape both the therapy focus and the conversation with a prescriber.

A medical contributor may be involved. Thyroid dysfunction, certain vitamin deficiencies, chronic pain, sleep disorders, and some medications can all mimic or worsen depression. These belong on the checklist with a medical provider before concluding a depression is treatment-resistant [1].

The through-line is that "resistance" is frequently a signal to reassess, not just to re-medicate. A fresh, structured evaluation exists precisely to surface these missed or misdiagnosed factors — the bipolar spectrum, ADHD, trauma, anxiety, the medical contributors — so the next treatment is aimed at the right target.

🔍 Key takeaway: A large share of "treatment resistance" comes from an inadequate trial or an incomplete diagnosis — both of which a careful reassessment can catch.

What options exist

There is no single next step that fits everyone, but the real menu is wider than most people realize. Broadly, options fall into a few categories, and they are often combined.

Psychotherapy — including after medication has stalled

Therapy is not a consolation prize for when medication fails; it is an evidence-based treatment in its own right, and it works through different mechanisms than medication does. The clearest evidence comes from the CoBalT randomized trial, which added cognitive behavioral therapy to usual care for people whose depression had not responded to antidepressants. Adding CBT roughly doubled the response rate compared with continuing medication alone — 46% versus 22% at six months — with benefits that held up over the following years [5]. Major clinical guidelines list structured psychotherapies alongside medication as first-line and next-line options [7][8]. Practically, this means therapy is one of the strongest evidence-backed moves available when a medication-only plan has stalled — and it can be started while other decisions are still being sorted out.

Adjusting medication — a prescriber's domain

Beyond therapy, the medication strategy itself can change: switching to a different class, combining two antidepressants, or augmenting with another agent such as lithium, thyroid hormone, or an atypical antipsychotic [1][7]. These are prescriber-directed decisions that belong with a physician or psychiatric provider who can weigh the benefits and risks for your situation. We are a psychology practice and do not prescribe medication; what we can do is help you track response, organize the picture, and coordinate with the prescriber who does.

Clinician-directed procedures: TMS, ECT, and esketamine

For depression that has resisted several steps, there are established treatments that go beyond oral medication. These are directed and delivered by medical providers, and we describe them here only so you know the landscape — not as recommendations for any individual.

• Transcranial magnetic stimulation (TMS) uses magnetic pulses to stimulate mood-related brain regions. It has been FDA-cleared for depression since 2008 and is supported by multiple randomized trials, typically for people who have not responded to at least one adequate medication trial [11].

• Electroconvulsive therapy (ECT) remains one of the most effective treatments for severe or resistant depression, with remission rates commonly reported around 60–70%, and a particular role when symptoms are severe, psychotic, or urgently dangerous [10]. Modern ECT is delivered under anesthesia and is very different from its portrayal in popular media.

• Esketamine (Spravato), a nasal-spray medication given together with an oral antidepressant, was the first FDA-approved treatment in a genuinely new class for treatment-resistant depression, approved in 2019 and administered under medical supervision [6]. Research on ketamine-type treatments continues to evolve, and NIMH has funded much of the work behind rapidly acting options [9].

None of these are cures, and each carries its own considerations. The point is simply that the path does not dead-end at the second antidepressant.

Measurement-based care ties it together

Whatever the mix, plans work better when they are measured. Re-checking symptoms with the same validated scale at regular intervals — the logic behind our mental-health screening tools — lets you and your providers see whether a change is actually helping, and stop or adjust sooner when it is not [1].

🧩 Key takeaway: The real options span therapy, reassessment, prescriber-directed medication changes, and procedures like TMS, ECT, and esketamine — usually combined, and best guided by ongoing measurement.

Where therapy and assessment fit — and where they don't

It helps to be plain about roles, because a coordinated team beats any single provider working blind. As a psychology practice, our part of this picture is specific and honest.

We provide two things that matter a great deal when depression has not responded: psychotherapy with evidence-based approaches, and psychological assessment that can surface the missed or misdiagnosed factors described above. A thorough evaluation is often where a stalled plan gets unstuck — because it can distinguish unipolar depression from a bipolar-spectrum pattern, identify co-occurring ADHD, anxiety, or trauma, and hand you and your prescriber a clearer target.

What we do not do is prescribe or manage medication, order labs, or deliver ECT, TMS, or esketamine — those belong with a physician or psychiatric provider. When your situation calls for them, the most useful thing we can do is coordinate: share assessment findings, help you prepare for the medical conversation, and make a referral so the pieces fit together rather than working at cross purposes. If you want to talk through where you are and what kind of support fits, you can reach our team.

A simple way to decide your next move

If you are staring at "what now," a rough decision guide can help:

• If your last medication trial was short, low-dose, or interrupted, the next step may be as simple as revisiting that trial with your prescriber before concluding anything is resistant.

• If you have had two adequate trials and something about the diagnosis feels off — brief highs, lifelong attention struggles, trauma in the background — a fresh assessment is likely the highest-value next step.

• If the diagnosis feels right but the plan has plateaued, adding evidence-based therapy or discussing augmentation and procedures with a prescriber are the strongest moves.

• If symptoms are severe or you are having thoughts of not being safe, that is an urgent medical conversation now, not a decision to sit with — contact your provider or emergency services.

📋 Key takeaway: Our role is therapy, assessment, and coordination — not prescribing; matching your next move to why the last plan stalled is what keeps you from repeating it.

Questions worth bringing to your next appointment

You can ask any provider these directly:

1. Was my last medication trial actually adequate in dose and duration, or should we optimize it before calling it a failure?

2. Have we considered whether something else — bipolar-spectrum patterns, ADHD, trauma, anxiety, or a medical issue like thyroid — could be part of what we are treating?

3. Would a structured psychological assessment help clarify the diagnosis before we change the plan again?

4. What are the options beyond another antidepressant — therapy as an add-on, augmentation, or procedures like TMS or ECT — and which fits my situation?

5. How will we measure whether the next change is working, and when will we check?

Getting support that fits

Treatment-resistant depression is a description of where your treatment stands right now — not a life sentence, and not a reflection of how hard you have tried. For a large share of people, the reason the first plan stalled is knowable and fixable: an under-treated trial, a missed diagnosis, or a strategy that needed to widen beyond a single medication. The next step is rarely "give up." More often it is "look closer, then aim better."

If you have been through a couple of medications and still feel stuck, a fresh look at the fuller picture — and a plan built around it — can change what happens next.

Feeling weighed down lately?

Depression is treatable, and the right support makes a difference — a clinician can help you understand what's going on and what would help you feel like yourself again.

Schedule a depression consultation →

Frequently Asked Questions

How many antidepressants make depression treatment-resistant?

Most definitions use two or more adequate antidepressant trials — meaning the right dose for a long enough time — without reaching remission. The exact threshold varies between guidelines, and some definitions add that the medications should come from different classes. Before the label is applied, a clinician should confirm that the dose, duration, and day-to-day adherence were actually adequate, since an under-treated trial is not the same as a failed one.

Is treatment-resistant depression permanent?

No. The term describes depression that has not responded to the first treatments tried — not a permanent or untreatable state. Many people improve with a different approach, a combination of treatments, or a reassessment that finds a missed factor. Response can also take time, and the available options continue to grow. It is more accurate to read treatment-resistant as 'not yet responded' than as 'beyond help.'

Does therapy help treatment-resistant depression?

Yes, for many people. In a large randomized trial, adding cognitive behavioral therapy to ongoing medication roughly doubled the response rate compared with staying on medication alone. Therapy can also reach patterns that medication does not, such as rumination, avoidance, or unprocessed trauma. It is usually used alongside a prescriber's plan rather than in place of one, which is where care coordination matters.

Can a new psychological assessment help if antidepressants aren't working?

Sometimes, yes. When depression is not improving, a fresh diagnostic assessment can surface factors the first treatment may have missed — such as bipolar-spectrum patterns, ADHD, trauma, or a medical contributor like thyroid dysfunction. Naming the fuller picture can change which treatment makes sense. An assessment does not replace medication management, but it can make the whole plan more precise and less trial-and-error.

What's the difference between treatment-resistant depression and partial response?

Treatment-resistant depression usually means no remission after two or more adequate antidepressant trials. Partial response is different — it means symptoms dropped by less than about half, so there is real improvement but not enough. The distinction matters clinically: partial response often points toward adjusting or augmenting the current treatment, while fuller resistance may call for a broader rethink of the diagnosis and the plan.

About the Author

Dr. Kiesa Kelly is a licensed clinical psychologist and the founder of ScienceWorks Behavioral Healthcare, with more than 20 years of experience in psychological assessment and evidence-based treatment. Her background centers on differential diagnosis and comprehensive evaluation — the kind of careful assessment that distinguishes depression from bipolar-spectrum, ADHD, trauma, and anxiety presentations that can be mistaken for one another when a treatment plan stalls.

Dr. Kelly's clinical training spans major research and academic settings, and her work emphasizes matching people to the right treatment target rather than defaulting to trial-and-error. At ScienceWorks, she leads a clinician team providing telehealth-forward assessment and therapy across Tennessee, with an in-person option in Nashville, and every article here is reviewed by a licensed clinician for accuracy before publication.

References

1. Naik A. Depression: Managing Resistance and Partial Response to Treatment. American Family Physician. 2024;109(5):410-416. https://www.aafp.org/pubs/afp/issues/2024/0500/treatment-resistant-depression.html

2. McIntyre RS, Alsuwaidan M, Baune BT, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394-412. https://onlinelibrary.wiley.com/doi/full/10.1002/wps.21120

3. Pigott HE, Kim T, Xu C, Kirsch I, Amsterdam J. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study's patient-level data. BMJ Open. 2023;13(7):e063095. https://pmc.ncbi.nlm.nih.gov/articles/PMC10373710/

4. Insel TR, Wang PS. Translating Science Into Service: Lessons Learned From the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study. Primary Care Companion to the Journal of Clinical Psychiatry. https://pmc.ncbi.nlm.nih.gov/articles/PMC2040279/

5. Wiles N, Thomas L, Abel A, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. The Lancet. 2013;381(9864):375-384. https://pubmed.ncbi.nlm.nih.gov/23219570/

6. Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class. New England Journal of Medicine. 2019;381(1):1-4. https://www.nejm.org/doi/abs/10.1056/NEJMp1903305

7. American Psychological Association. Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. 2019. https://www.apa.org/depression-guideline

8. National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. NICE guideline [NG222]. 2022. https://www.nice.org.uk/guidance/ng222

9. National Institute of Mental Health. Depression. https://www.nimh.nih.gov/health/topics/depression

10. Kaster TS, Vigod SN, Gomes T, Sutradhar R, Wijeysundera DN, Blumberger DM. Effectiveness of Electroconvulsive Therapy for Preventing Relapse and Recurrence of Depression in Adults With Major Depressive Disorder: An Updated Meta-Analysis of Randomized Clinical Trials. https://pmc.ncbi.nlm.nih.gov/articles/PMC10066659/

11. Cohen SL, Bikson M, Badran BW, George MS. Consensus review and considerations on transcranial magnetic stimulation to treat depression. Clinical Neurophysiology. 2024. https://www.sciencedirect.com/science/article/pii/S1388245724003766

Disclaimer

This article is for informational and educational purposes only and is not a substitute for professional medical or mental-health advice, diagnosis, or treatment. It does not establish a provider-patient relationship. Medication decisions, including starting, stopping, or changing any treatment, and procedures such as ECT, TMS, or esketamine, should be made with a qualified prescribing or medical provider. If you are in crisis or thinking about harming yourself, call or text 988 (the Suicide and Crisis Lifeline) in the U.S., or call 911 or go to your nearest emergency room.